Phosphodiesterase 5A as a target in cardiac disease.
Doggrell
Sheila A
SA
Auckland University of Technology, Division of Health Practice, Akoranga Campus, Northcote, Auckland, New Zealand. S_doggrell@yahoo.com
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity; D006332:Cardiomegaly / Q000139:chemically induced / Q000188:drug therapy*; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004317:Doxorubicin / Q000633:toxicity; D051379:Mice; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines; D051381:Rats; D000068677:Sildenafil Citrate; D013450:Sulfones
D000903:Antibiotics, Antineoplastic; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D004317:Doxorubicin; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517382:Pde5a protein, mouse; C517384:Pde5a protein, rat